Akorn down 7% premarket on slim chances of reviving Fresenius deal

|By:, SA News Editor

Akorn (NASDAQ:AKRX) slips 7% premarket on light volume in apparent reaction to the low probability that it will successful in its appeal of a court decision allowing former suitor Fresenius SE (OTCQX:FSNUF) to back out of its $4.75B takeover.

Bloomberg reports that MDC Financial Research's Michael Cohen viewed the hearing online and believes that there is "very little chance" that the decision will be reversed.

Previously: Akorn down 12% ahead of hearing on disputed Fresenius merger (Aug. 23)

Subscribe for full text news in your inbox